FenoterolFenoterol
MedChemExpress (MCE)
HY-B0976
13392-18-2
Th-1165
Phenoterol
98.86%
4°C, protect from light *In solvent : -80°C, 6 months
-20°C, 1 month (protect from light)
Room temperature in continental US
may vary elsewhere.
Fenoterol (Th-1165), a sympathomimetic agent, is a selective and orally active β2-adrenoceptor agonist. Fenoterol is an effective bronchodilator and can be used for bronchospasm associated with asthma, bronchitis and other obstructive airway diseases research.
Fenoterol (1 μM
pre-incubated 30 minutes) treatment reduces AICAR-induced AMPK activation, NF-κB activation and TNF-α release, and also significantly downregulates the elevated phosphorylation levels of AMPK[2]. Fenoterol inhibits lipopolysaccharide (LPS)-induced AMPK activation and inflammatory cytokine production in THP-1 cells[2]. Fenoterol is also a potent exosome biogenesis and/or secretion activator in PC cells[4].
Fenoterol (0.7 mg/kg
intraperitoneal injection
twice a day
for 3 weeks) treatment suppresses mechanical allodynia during chronic treatment[3].
β adrenergic receptor
| | | |
| | | | | |
[1]. R C Heel, et al. Fenoterol: a review of its pharmacological properties and therapeutic efficacy in asthma. Drugs. 1978 Jan
15(1):3-32. [Content Brief]
[2]. Wei Wang, et al. Anti-inflammatory activities of fenoterol through β-arrestin-2 and inhibition of AMPK and NF-κB activation in AICAR-induced THP-1 cells. Biomed Pharmacother. 2016 Dec
84:185-190. [Content Brief]
[3]. Nada Choucair-Jaafar, et al. Beta2-adrenoceptor agonists alleviate neuropathic allodynia in mice after chronic treatment. Br J Pharmacol. 2009 Dec
158(7):1683-94. [Content Brief]
[4]. Amrita Datta, et al. High-throughput screening identified selective inhibitors of exosome biogenesis and secretion: A drug repurposing strategy for advanced cancer. Sci Rep. 2018 May 25
8(1):8161. [Content Brief]